Elizabeth M Brunt

Author PubWeight™ 201.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 29.57
2 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010 13.33
3 The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 11.03
4 A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008 10.84
5 The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012 5.47
6 AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007 3.73
7 Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011 3.37
8 Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010 3.36
9 Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003 3.23
10 Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007 3.18
11 Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004 3.00
12 Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012 2.89
13 Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009 2.88
14 Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010 2.86
15 Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008 2.45
16 Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011 2.44
17 The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011 2.42
18 Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011 2.15
19 Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009 2.07
20 Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 2010 1.98
21 Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg 2012 1.91
22 Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2012 1.83
23 Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013 1.77
24 Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007 1.76
25 Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012 1.70
26 Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002 1.68
27 Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008 1.68
28 Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012 1.68
29 Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008 1.67
30 Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J Clin Invest 2014 1.63
31 The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012 1.61
32 Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005 1.54
33 Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006 1.49
34 Hepatic iron overload in blacks and whites: a comparative autopsy study. Am J Gastroenterol 2003 1.49
35 What's in a NAme? Hepatology 2009 1.49
36 Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2009 1.48
37 Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008 1.42
38 Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009 1.37
39 Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012 1.27
40 Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009 1.26
41 Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 2008 1.20
42 Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 2002 1.18
43 Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010 1.14
44 Hepatic steatosis, inflammation, and ER stress in mice maintained long term on a very low-carbohydrate ketogenic diet. Am J Physiol Gastrointest Liver Physiol 2011 1.13
45 Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 2010 1.12
46 Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice. J Lipid Res 2009 1.12
47 Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011 1.11
48 Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res 2009 1.08
49 Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009 1.08
50 Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2013 1.08
51 The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hepatology 2008 1.07
52 Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology 2008 1.07
53 Biliary-venous fistula complicating transjugular intrahepatic portosystemic shunt presenting with recurrent bacteremia, jaundice, anemia and fever. Am J Transplant 2003 1.04
54 Diabetic hepatosclerosis: diabetic microangiopathy of the liver. Arch Pathol Lab Med 2006 1.02
55 Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. Liver Transpl 2011 1.00
56 Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005 0.97
57 Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int 2013 0.97
58 Diabetic hepatosclerosis: a 10-year autopsy series. Liver Int 2009 0.97
59 Polypoid lesions of the gallbladder: disease spectrum with pathologic correlation. Radiographics 2015 0.94
60 Hepatic expression of cell death-inducing DFFA-like effector C in obese subjects is reduced by marked weight loss. Obesity (Silver Spring) 2009 0.94
61 SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014 0.94
62 Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003 0.94
63 Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2010 0.93
64 Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 2010 0.93
65 Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations. Hepatology 2012 0.93
66 Bone marrow biopsy in patients with hepatitis C virus infection: spectrum of findings and diagnostic utility. Am J Hematol 2010 0.92
67 Misuse of scoring systems. Hepatology 2011 0.91
68 Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology 2013 0.91
69 Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012 0.91
70 Characteristics of hepatocellular carcinoma in a murine model of alpha-1-antitrypsin deficiency. Hepatol Res 2010 0.91
71 American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010 0.91
72 Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver. Lab Invest 2005 0.90
73 Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011 0.90
74 Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease. Hum Pathol 2011 0.89
75 Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011 0.89
76 CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. J Lipid Res 2013 0.89
77 Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients. Am J Surg Pathol 2007 0.88
78 Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002 0.88
79 Nonalcoholic fatty liver disease. Clin Liver Dis 2010 0.86
80 Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am J Gastroenterol 2003 0.86
81 Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids 2012 0.86
82 Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 2014 0.85
83 Hepatocellular carcinoma: predisposing conditions and precursor lesions. Gastroenterol Clin North Am 2002 0.85
84 Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interferon Cytokine Res 2002 0.85
85 Short- and long-term outcomes after steatotic liver transplantation. Arch Surg 2010 0.85
86 Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol 2013 0.85
87 Keratin 19 epithelial patterns in cirrhotic stroma parallel hepatocarcinogenesis. Am J Pathol 2011 0.84
88 Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003 0.84
89 Fighting the bushfire in HCC trials. J Hepatol 2011 0.84
90 Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. Liver Int 2006 0.83
91 CD14-positive hepatic monocytes/macrophages increase in hereditary hemochromatosis. Liver Int 2004 0.83
92 The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology 2007 0.82
93 Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003 0.82
94 Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One 2013 0.82
95 Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases. Arch Pathol Lab Med 2014 0.82
96 Role of choline deficiency in the Fatty liver phenotype of mice fed a low protein, very low carbohydrate ketogenic diet. PLoS One 2013 0.81
97 Validation of organ procurement and transplant network (OPTN)/united network for organ sharing (UNOS) criteria for imaging diagnosis of hepatocellular carcinoma. Transplantation 2013 0.81
98 Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2011 0.81
99 Do you see what I see? The role of quality histopathology in scientific study. Hepatology 2008 0.81
100 Histological features and severity of oxaliplatin-induced liver injury and clinical associations. J Dig Dis 2014 0.80
101 Surgical assessment of significant steatosis in donor livers: the beginning of the end for frozen-section analysis? Liver Transpl 2013 0.79
102 Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2013 0.79
103 Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int 2013 0.78
104 Hepatocellular progenitor cell tumor of the gallbladder: a case report and review of the literature. Mod Pathol 2005 0.78
105 Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis. J Lab Clin Med 2005 0.77
106 Parenchymal alterations in cirrhotic livers in patients with hepatopulmonary syndrome or portopulmonary hypertension. Liver Transpl 2013 0.77
107 Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma: detection by immunostaining. Dig Dis Sci 2002 0.76
108 Coexistence of inflammatory hepatocellular adenomas with HNF1α-inactivated adenomas: is there an association? Histopathology 2014 0.76
109 Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Biochem Biophys Res Commun 2011 0.75
110 Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl 2007 0.75
111 Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight. J Pediatr Gastroenterol Nutr 2016 0.75
112 Polypoid lesions of the gallbladder: disease spectrum with pathologic correlation-erratum. Radiographics 2015 0.75
113 Best cases from the AFIP: multiple gastric carcinoids. Radiographics 2009 0.75
114 A 32-year-old man with hepatitis C who developed progressive liver failure after a bone marrow transplant. Semin Liver Dis 2002 0.75
115 Histopathologic evaluation of liver biopsy for cirrhosis. Adv Anat Pathol 2012 0.75
116 Familial adenomatous polyposis-associated ampullary adenoma: response to chemotherapy for concurrent metastatic adenocarcinoma. Clin Gastroenterol Hepatol 2009 0.75
117 Evaluating liver disease in chronic hepatitis C--the role of the liver biopsy. MedGenMed 2003 0.75
118 Polypoid Lesions of the Gallbladder: Disease Spectrum with Pathologic Correlation—Erratum. Radiographics 2015 0.75